<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224351</url>
  </required_header>
  <id_info>
    <org_study_id>VX16-659-101</org_study_id>
    <secondary_id>2016-003585-11</secondary_id>
    <nct_id>NCT03224351</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo- and tezacaftor/ivacaftor
      (TEZ/IVA)-controlled, parallel-group, 3-part, multicenter study designed to evaluate the
      safety and efficacy of VX-659 in triple combination (TC) with TEZ and IVA in subjects with
      cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane
      conductance regulator (CFTR) gene (F/F genotype), or who are heterozygous for the F508del
      mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ, IVA, or
      TEZ/IVA (F/MF genotypes).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2017</start_date>
  <completion_date type="Actual">February 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From baseline through safety follow-up (20 Weeks)</time_frame>
    <description>Number of subjects with AEs and SAEs will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)</measure>
    <time_frame>from baseline through Day 29</time_frame>
    <description>Absolute change in ppFEV1 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in sweat chloride concentrations</measure>
    <time_frame>from baseline through Day 29</time_frame>
    <description>Absolute change in sweat chloride concentrations will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in ppFEV1</measure>
    <time_frame>from baseline through Day 29</time_frame>
    <description>Relative change in ppFEV1 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score</measure>
    <time_frame>from baseline at Day 29</time_frame>
    <description>The absolute change in CFQ-R respiratory domain score will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of VX-659, TEZ, M1-TEZ, IVA, M1-IVA, and VX-561</measure>
    <time_frame>from Day 1 through Day 29</time_frame>
    <description>Maximum plasma concentration [CMax] will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-659, TEZ, M1-TEZ, IVA, M1-IVA, and VX-561</measure>
    <time_frame>from Day 1 through Day 29</time_frame>
    <description>The area under the plasma concentration time curve over the dosing interval (AUCtau) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pre-dose concentration (Ctrough) of VX-659, TEZ, M1-TEZ, IVA, M1-IVA, and VX-561</measure>
    <time_frame>from Day 1 through Day 29</time_frame>
    <description>The observed predose concentration (Ctrough) will be reported.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part 1: F/MF genotype -TC Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 80 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: F/MF genotype - TC Mid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 240 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: F/MF genotype - TC High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 400 mg VX-659 qd in TC with TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: F/MF genotype - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: F/F genotype - TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 400 mg of VX-659 qd in TC with TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: F/F genotype - TEZ/IVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive TEZ and IVA for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: F/MF genotype - TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 400 mg of VX-659 qd in TC with TEZ and VX-561 for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: F/MF genotype - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEZ/IVA</intervention_name>
    <description>100-mg TEZ/150-mg IVA fixed-dose combination (FDC) tablet for oral administration</description>
    <arm_group_label>Part 1: F/MF genotype -TC Low</arm_group_label>
    <arm_group_label>Part 1: F/MF genotype - TC Mid</arm_group_label>
    <arm_group_label>Part 1: F/MF genotype - TC High</arm_group_label>
    <arm_group_label>Part 2: F/F genotype - TC</arm_group_label>
    <arm_group_label>Part 2: F/F genotype - TEZ/IVA</arm_group_label>
    <other_name>VX-661/VX-770</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-659</intervention_name>
    <description>80-mg VX-659 tablet for oral administration</description>
    <arm_group_label>Part 1: F/MF genotype -TC Low</arm_group_label>
    <arm_group_label>Part 1: F/MF genotype - TC Mid</arm_group_label>
    <arm_group_label>Part 1: F/MF genotype - TC High</arm_group_label>
    <arm_group_label>Part 2: F/F genotype - TC</arm_group_label>
    <arm_group_label>Part 3: F/MF genotype - TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>150-mg IVA tablet for oral administration</description>
    <arm_group_label>Part 1: F/MF genotype -TC Low</arm_group_label>
    <arm_group_label>Part 1: F/MF genotype - TC Mid</arm_group_label>
    <arm_group_label>Part 1: F/MF genotype - TC High</arm_group_label>
    <arm_group_label>Part 2: F/F genotype - TC</arm_group_label>
    <arm_group_label>Part 2: F/F genotype - TEZ/IVA</arm_group_label>
    <other_name>VX-770</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebos</intervention_name>
    <description>Placebo will be used as a comparator.</description>
    <arm_group_label>Part 1: F/MF genotype - Placebo</arm_group_label>
    <arm_group_label>Part 2: F/F genotype - TEZ/IVA</arm_group_label>
    <arm_group_label>Part 3: F/MF genotype - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEZ</intervention_name>
    <description>50-mg tablet for oral administration.</description>
    <arm_group_label>Part 3: F/MF genotype - TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-561</intervention_name>
    <description>50-mg VX-561 tablet for oral administration.</description>
    <arm_group_label>Part 3: F/MF genotype - TC</arm_group_label>
    <other_name>CTP-656</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Body weight ≥35 kg.

          -  Subjects must have an eligibleCFTR genotype.

               -  Part 1 and Part 3: Heterozygous for F508del and an MF mutation (F/MF)

               -  Part 2: Homozygous for F508del (F/F)

          -  FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height

        Key Exclusion Criteria:

          -  History of clinically significant cirrhosis with or without portal hypertension.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Lung infection with organisms associated with a more rapid decline in pulmonary
             status.

          -  History of solid organ or hematological transplantation.

        Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital - Park Ridge / North Suburban Pulmonary and Critical Care Consultants</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital/ Johns Hopkins Hospital, David Rubenstein Child Health Building</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital CF Center</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers-Robert Wood Johnson Medical School/ Rutgers-Robert Wood Johnson Medical School, Clinical Research Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health, Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Diseases of Children &amp; Adolescents</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Research / USD</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center-Adult Cystic Fibrosis Clinic</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Foundation Research Center / Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah / Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Pediatric Pulmonary &amp; Allergy/Immunology Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's University Hosptial</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galway University Hospitals</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruth Children's Hospital Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba medical center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Tikvah</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B95SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust, Papworth Everard</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Llandough in Cardiff</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital</name>
      <address>
        <city>Devon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust, The Royal Victoria Infirmary</name>
      <address>
        <city>Fulham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Glasgow and Clyde NHS Board, Glasgow Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Hampshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Respiratory Centre Belfast City Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefied NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester NHS Trust, North West Lung Centre</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Merseyside</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruth Children's Hospital Rambam Health Care Campus</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Israel</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

